Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus

Clinical Transplantation

Volumn 28, Issue 12, 2014, Pages 1410-1415

  Lutz, Mathias ^a   Kapp, Markus ^a   Einsele, Hermann ^a   Grigoleit, Götz Ulrich ^a   Mielke, Stephan ^a  

^a Würzburg University Medical Center   (Germany)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Chronic graft versus host disease; Everolimus; Quality of life; Retrospective analysis

Indexed keywords

CYCLOSPORIN A; ETANERCEPT; EVEROLIMUS; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BOTHERSOMENESS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; FEMALE; HUMAN; LEE CGVHD SYMPTOM SCALE; MALE; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SALVAGE THERAPY; STEROID THERAPY; TREATMENT DURATION; VISUAL ANALOG SCALE; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; CLINICAL TRIAL; FOLLOW UP; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; PSYCHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84918828951     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12472     Document Type: Article

References (25)

1. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003: 9: 215.
2. Tyndall A, Dazzi F. Chronic GVHD as an autoimmune disease. Best Pract Res Clin Haematol 2008: 21: 281.
3. Hilgendorf I, Wolff D, Nogai A et al. Chronic graft versus host disease but not the intensity of conditioning has impact on survival after allogeneic hematopoietic stem cell transplantation for advanced hematological diseases. Onkologie 2012: 35: 487.
4. Vargas-Diez E, Garcia-Diez A, Marin A et al. Life-threatening graft-vs-host disease. Clin Dermatol 2005: 23: 285.
5. Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood 2014: 124: 374.
6. Savani BN, Griffith ML, Jagasia S et al. How I treat late effects in adults after allogeneic stem cell transplantation. Blood 2011: 117: 3002.
7. Alousi AM, Bolanos-Meade J, Lee SJ. Graft-versus-host disease: state of the science. Biol Blood Marrow Transplant 2013: 19: S102.
8. Dignan FL, Manwani R, Potter MN et al. A dedicated GvHD clinic may improve the quality of life for allogeneic stem cell transplant survivors. Clin Transplant 2013: 27: E1.
9. Wood WA, Chai X, Weisdorf D et al. Comorbidity burden in patients with chronic GVHD. Bone Marrow Transplant 2013: 48: 1429.
10. Sun CL, Francisco L, Baker KS et al. Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood 2011: 118: 4723.
11. Flowers ME, Storer B, Carpenter P et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008: 14: 1380.
12. Arora M, Burns LJ, Davies SM et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant 2003: 9: 38.
13. Bastien JP, Krosl G, Therien C et al. Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease. Blood 2010: 116: 4859.
14. Mielke S, Lutz M, Schmidhuber J et al. Salvage therapy with everolimus reduces the severity of treatment-refractory chronic graft-versus-host disease without impairing disease control: A dual center retrospective analysis. Bone Marrow Transplant 2014: 49: 1412.
15. Lee S, Cook EF, Soiffer R et al. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002: 8: 444.
16. Inamoto Y, Flowers ME. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol 2011: 18: 414.
17. Inamoto Y, Storer BE, Lee SJ et al. Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood 2013: 121: 2340.
18. Mitchell SA, Leidy NK, Mooney KH et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 2010: 45: 762.
19. Andersson HI, Ejlertsson G, Leden I et al. Impact of chronic pain on health care seeking, self care, and medication. Results from a population-based Swedish study. J Epidemiol Community Health 1999: 53: 503.
20. Coast J, Peters TJ, Richards SH et al. Use of the EuroQoL among elderly acute care patients. Qual Life Res 1998: 7: 1.
21. Conn VS, Taylor SG, Wiman P. Anxiety, depression, quality of life, and self-care among survivors of myocardial infarction. Issues Ment Health Nurs 1991: 12: 321.
22. Sarkar S, Scherwath A, Schirmer L et al. Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT. Bone Marrow Transplant 2014: 49: 1217.
23. Hefner J, Kapp M, Drebinger K et al. High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age. Bone Marrow Transplant 2014: 49: 581.
24. Lutz M, Kapp M, Grigoleit GU et al. Salvage therapy of refractory chronic graft-versus-host disease with everolimus is associated with a significant reduction of bother in the majority of patients. Onkologie 2011: 34(Suppl 6): S282 (P930).
25. Lutz M, Kapp M, Grigoleit GU et al. Salvage therapy with everolimus improves quality of life in patients with refractory chronic graft-versus-host disease. Bone Marrow Transplant 2012: 47(Suppl 1): S410 (P1068).